PULSE CARDIAC DIAGNOSTIC LTD 14325746 false 2022-08-30 2023-08-31 2023-08-31 The principal activity of the company is cardiological practice Digita Accounts Production Advanced 6.30.9574.0 true 14325746 2022-08-30 2023-08-31 14325746 2023-08-31 14325746 core:RetainedEarningsAccumulatedLosses 2023-08-31 14325746 core:ShareCapital 2023-08-31 14325746 core:CurrentFinancialInstruments core:WithinOneYear 2023-08-31 14325746 core:FurnitureFittingsToolsEquipment 2023-08-31 14325746 bus:SmallEntities 2022-08-30 2023-08-31 14325746 bus:AuditExemptWithAccountantsReport 2022-08-30 2023-08-31 14325746 bus:AbridgedAccounts 2022-08-30 2023-08-31 14325746 bus:SmallCompaniesRegimeForAccounts 2022-08-30 2023-08-31 14325746 bus:RegisteredOffice 2022-08-30 2023-08-31 14325746 bus:Director1 2022-08-30 2023-08-31 14325746 bus:PrivateLimitedCompanyLtd 2022-08-30 2023-08-31 14325746 bus:Agent1 2022-08-30 2023-08-31 14325746 core:FurnitureFittingsToolsEquipment 2022-08-30 2023-08-31 14325746 countries:EnglandWales 2022-08-30 2023-08-31 iso4217:GBP xbrli:pure

Registration number: 14325746

PULSE CARDIAC DIAGNOSTIC LTD

Unaudited Abridged Financial Statements

(Companies House version)

for the Period from 30 August 2022 to 31 August 2023

 

PULSE CARDIAC DIAGNOSTIC LTD

Contents

Accountants' Report

1

Abridged Balance Sheet

2 to 3

Notes to the Unaudited Abridged Financial Statements

4 to 6

 

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
PULSE CARDIAC DIAGNOSTIC LTD
for the Period Ended 31 August 2023

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of PULSE CARDIAC DIAGNOSTIC LTD for the period ended 31 August 2023 as set out on pages 2 to 6 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com/en/members/regulations-standards-and-guidance/.

This report is made solely to the Board of Directors of PULSE CARDIAC DIAGNOSTIC LTD, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of PULSE CARDIAC DIAGNOSTIC LTD and state those matters that we have agreed to state to the Board of Directors of PULSE CARDIAC DIAGNOSTIC LTD, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than PULSE CARDIAC DIAGNOSTIC LTD and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that PULSE CARDIAC DIAGNOSTIC LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of PULSE CARDIAC DIAGNOSTIC LTD. You consider that PULSE CARDIAC DIAGNOSTIC LTD is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or a review of the accounts of PULSE CARDIAC DIAGNOSTIC LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Page Kirk LLP
Chartered accountants and chartered tax advisers
Sherwood House
7 Gregory Boulevard
Nottingham
NG7 6LB

24 November 2023

 

PULSE CARDIAC DIAGNOSTIC LTD

(Registration number: 14325746)
Abridged Balance Sheet as at 31 August 2023

Note

2023

   

£

£

Fixed assets

   

Tangible assets

4

 

928

Current assets

   

Cash at bank and in hand

 

82,264

 

Creditors: Amounts falling due within one year

(82,659)

 

Net current liabilities

   

(395)

Total assets less current liabilities

   

533

Provisions for liabilities

 

(246)

Net assets

   

287

Capital and reserves

   

Called up share capital

100

 

Profit and loss account

187

 

Total equity

   

287

 

PULSE CARDIAC DIAGNOSTIC LTD

(Registration number: 14325746)
Abridged Balance Sheet as at 31 August 2023

For the financial period ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 24 November 2023 and signed on its behalf by:
 

.........................................
Dr M M Ansari
Director

 

PULSE CARDIAC DIAGNOSTIC LTD

Notes to the Unaudited Abridged Financial Statements for the Period from 30 August 2022 to 31 August 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Sherwood House
7 Gregory Boulevard
Nottingham
Nottinghamshire
NG7 6LB

These financial statements were authorised for issue by the Board on 24 November 2023.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Basis of preparation of financial statements

These financial statements were prepared under the historical cost convention in accordance with applicable United Kingdom accounting standards, including the Financial Reporting Standard 102 ('FRS 102') Section 1A small entities, and with the Companies Act 2006.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

PULSE CARDIAC DIAGNOSTIC LTD

Notes to the Unaudited Abridged Financial Statements for the Period from 30 August 2022 to 31 August 2023

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

During the period, the average number of employees at the company was 2.

 

PULSE CARDIAC DIAGNOSTIC LTD

Notes to the Unaudited Abridged Financial Statements for the Period from 30 August 2022 to 31 August 2023

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

Additions

1,237

1,237

At 31 August 2023

1,237

1,237

Depreciation

Charge for the period

309

309

At 31 August 2023

309

309

Carrying amount

At 31 August 2023

928

928